相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liquid Biopsies, Novel Approaches and Future Directions
Athanasios Armakolas et al.
CANCERS (2023)
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Anna Buder et al.
TARGETED ONCOLOGY (2021)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
Mechanisms of osimertinib resistance and emerging treatment options
Sabine Schmid et al.
LUNG CANCER (2020)
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
Anna Buder et al.
TARGETED ONCOLOGY (2019)
LBA17Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
T Reungwetwattana et al.
ANNALS OF ONCOLOGY (2019)
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Maximilian J. Hochmair et al.
TARGETED ONCOLOGY (2019)
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Bin-Chi Liao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
J. Remon et al.
ANNALS OF ONCOLOGY (2018)
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR- Mutated NSCLC
Anna Buder et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
Joan Rou-En Choo et al.
TARGETED ONCOLOGY (2018)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich et al.
CLINICAL CANCER RESEARCH (2016)
The potential of liquid biopsies
Anna Buder et al.
CURRENT OPINION IN ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
